IRF6 and breast carcinoma: Downregulation of IRF6 was demonstrated in highly invasive breast cancer cell lines and when elevated, it suppressed cell proliferation, and enhanced sensitivity to chemotherapy [58], but the impacts of IRF6 on cardiovascular diseases remain largely unknown [59].